Xarelto

DRUG3 trials

Sponsors

University Hospital, Montpellier, Assistance Publique - Hôpitaux de Paris, Genuine Research Center, Egypt

Conditions

Chronic Portal Vein ThrombosisDeep Vein ThrombosisHealthyNon-valvular Atrial Fibrillation

Phase 1

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

CompletedNCT03071380

Genuine Research Center, EgyptHealthy

Start: 2015-02-28End: 2015-03-31Updated: 2019-08-01

Phase 3

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

CompletedNCT02555111

Assistance Publique - Hôpitaux de ParisChronic Portal Vein Thrombosis, Deep Vein Thrombosis

Start: 2015-09-30End: 2020-02-29Updated: 2022-07-26

Unknown Phase

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

CompletedNCT02422602

University Hospital, MontpellierNon-valvular Atrial Fibrillation

Start: 2013-11-26End: 2016-05-06Updated: 2021-07-26

Related Papers

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis

NEJM Evidence2022-11-2251 citations